Small Cell Transformation in a Patient With RET Fusion-Positive Lung Adenocarcinoma on Pralsetinib

JCO Precis Oncol. 2022 Dec:6:e2200478. doi: 10.1200/PO.22.00478.

Authors

Anastasios Dimou¹, Ying-Chun Lo², Kenneth W Merrell³, Kevin C Halling², Aaron S Mansfield¹

Affiliations

¹ Department of Oncology, Mayo Clinic, Rochester, MN.
² Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
³ Department of Radiation Oncology, Mayo Clinic, Rochester, MN.

PMID: 36542817
DOI: 10.1200/PO.22.00478

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adenocarcinoma of Lung* / drug therapy
Adenocarcinoma of Lung* / genetics
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Lung Neoplasms* / pathology
Proto-Oncogene Proteins c-ret / genetics
Pyrazoles
Pyridines

Substances

pralsetinib
Pyridines
Pyrazoles
RET protein, human
Proto-Oncogene Proteins c-ret